 Enrique Alvarez
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 35 | 2024 | 380 | 8.480 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 11 | 2024 | 69 | 2.630 |
Why?
| | Immunologic Factors | 7 | 2020 | 221 | 2.590 |
Why?
| | Fingolimod Hydrochloride | 6 | 2020 | 30 | 2.420 |
Why?
| | Natalizumab | 5 | 2023 | 46 | 2.320 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 6 | 2023 | 25 | 2.250 |
Why?
| | Rituximab | 6 | 2023 | 150 | 1.860 |
Why?
| | Immunosuppressive Agents | 9 | 2024 | 651 | 1.480 |
Why?
| | Agammaglobulinemia | 2 | 2023 | 29 | 1.060 |
Why?
| | Dimethyl Fumarate | 3 | 2020 | 10 | 1.060 |
Why?
| | Neuromyelitis Optica | 4 | 2020 | 115 | 0.770 |
Why?
| | Serum Sickness | 1 | 2019 | 7 | 0.680 |
Why?
| | Pregnancy Complications | 2 | 2018 | 430 | 0.570 |
Why?
| | Medical Marijuana | 1 | 2018 | 97 | 0.560 |
Why?
| | Lymphocyte Depletion | 3 | 2021 | 116 | 0.530 |
Why?
| | Axons | 2 | 2014 | 177 | 0.520 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2023 | 665 | 0.500 |
Why?
| | Marijuana Smoking | 1 | 2018 | 224 | 0.500 |
Why?
| | Oligoclonal Bands | 1 | 2014 | 21 | 0.490 |
Why?
| | Neurofilament Proteins | 1 | 2014 | 34 | 0.480 |
Why?
| | Biomarkers | 3 | 2023 | 3419 | 0.480 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 937 | 0.460 |
Why?
| | Anemia | 1 | 2015 | 144 | 0.450 |
Why?
| | Humans | 51 | 2024 | 115042 | 0.440 |
Why?
| | Chemokine CXCL13 | 1 | 2013 | 7 | 0.430 |
Why?
| | Recurrence | 6 | 2024 | 941 | 0.430 |
Why?
| | Adult | 24 | 2023 | 30656 | 0.420 |
Why?
| | Antibodies, Monoclonal | 4 | 2022 | 1268 | 0.390 |
Why?
| | Middle Aged | 23 | 2024 | 26827 | 0.390 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1747 | 0.350 |
Why?
| | Female | 29 | 2024 | 59613 | 0.350 |
Why?
| | Brain | 7 | 2021 | 2380 | 0.330 |
Why?
| | Magnetic Resonance Imaging | 8 | 2022 | 3118 | 0.330 |
Why?
| | Walking | 4 | 2023 | 424 | 0.320 |
Why?
| | Glatiramer Acetate | 2 | 2019 | 20 | 0.300 |
Why?
| | Male | 23 | 2024 | 55731 | 0.270 |
Why?
| | B-Lymphocytes | 3 | 2023 | 772 | 0.270 |
Why?
| | Antigens, CD20 | 2 | 2023 | 28 | 0.270 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 60 | 0.250 |
Why?
| | Multigene Family | 1 | 2005 | 194 | 0.240 |
Why?
| | Demyelinating Diseases | 2 | 2022 | 75 | 0.240 |
Why?
| | Retrospective Studies | 8 | 2023 | 12547 | 0.230 |
Why?
| | Atrophy | 2 | 2021 | 151 | 0.220 |
Why?
| | Diphosphonates | 1 | 2003 | 51 | 0.220 |
Why?
| | Fatigue | 2 | 2024 | 295 | 0.220 |
Why?
| | Neuroprotection | 1 | 2023 | 30 | 0.220 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2003 | 64 | 0.220 |
Why?
| | Bone Resorption | 1 | 2003 | 73 | 0.220 |
Why?
| | Alemtuzumab | 1 | 2023 | 12 | 0.220 |
Why?
| | Inflammation | 1 | 2013 | 2485 | 0.200 |
Why?
| | Quality of Life | 4 | 2023 | 2359 | 0.200 |
Why?
| | Neuroblastoma | 1 | 2023 | 132 | 0.200 |
Why?
| | Drug Costs | 1 | 2023 | 91 | 0.200 |
Why?
| | Gadolinium | 2 | 2022 | 78 | 0.200 |
Why?
| | Interoception | 1 | 2021 | 2 | 0.200 |
Why?
| | Resistance Training | 1 | 2024 | 113 | 0.200 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 529 | 0.190 |
Why?
| | Diagnostic Self Evaluation | 1 | 2021 | 22 | 0.190 |
Why?
| | Stair Climbing | 1 | 2021 | 2 | 0.190 |
Why?
| | Killer Cells, Natural | 2 | 2021 | 383 | 0.190 |
Why?
| | Treatment Outcome | 6 | 2021 | 9122 | 0.180 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 799 | 0.180 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 111 | 0.180 |
Why?
| | Lymphopenia | 1 | 2020 | 50 | 0.180 |
Why?
| | Personality | 1 | 2021 | 114 | 0.180 |
Why?
| | Interferon-gamma | 1 | 2023 | 723 | 0.170 |
Why?
| | Cancer Vaccines | 1 | 2021 | 137 | 0.170 |
Why?
| | Muscle Strength | 2 | 2024 | 271 | 0.170 |
Why?
| | Neutropenia | 1 | 2020 | 125 | 0.170 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2019 | 17 | 0.170 |
Why?
| | Disease Management | 1 | 2023 | 563 | 0.170 |
Why?
| | Young Adult | 5 | 2021 | 10498 | 0.170 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 184 | 0.160 |
Why?
| | Double-Blind Method | 5 | 2022 | 1664 | 0.160 |
Why?
| | Nerve Net | 1 | 2021 | 225 | 0.160 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2018 | 82 | 0.150 |
Why?
| | Muscle Spasticity | 1 | 2018 | 53 | 0.150 |
Why?
| | Dendritic Cells | 1 | 2021 | 436 | 0.150 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 242 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4420 | 0.140 |
Why?
| | Electric Stimulation Therapy | 1 | 2018 | 56 | 0.140 |
Why?
| | Disease Progression | 5 | 2022 | 2389 | 0.140 |
Why?
| | Postural Balance | 1 | 2019 | 184 | 0.140 |
Why?
| | Psychomotor Performance | 1 | 2019 | 280 | 0.140 |
Why?
| | Interferon beta-1a | 1 | 2016 | 12 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 383 | 0.140 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2023 | 797 | 0.140 |
Why?
| | Lymphocyte Activation | 2 | 2019 | 1042 | 0.140 |
Why?
| | Transcription Factor RelA | 1 | 2016 | 83 | 0.130 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 78 | 0.130 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 719 | 0.130 |
Why?
| | CD40 Antigens | 1 | 2016 | 82 | 0.130 |
Why?
| | Physicians | 1 | 2023 | 772 | 0.130 |
Why?
| | Contrast Media | 1 | 2018 | 369 | 0.130 |
Why?
| | Neurons | 3 | 2011 | 1284 | 0.120 |
Why?
| | Postpartum Period | 1 | 2017 | 278 | 0.120 |
Why?
| | Pyridines | 1 | 2018 | 425 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 276 | 0.120 |
Why?
| | Survival Analysis | 1 | 2018 | 1211 | 0.120 |
Why?
| | Melanoma | 1 | 2021 | 622 | 0.120 |
Why?
| | Disability Evaluation | 4 | 2018 | 271 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2021 | 758 | 0.110 |
Why?
| | Muscle, Skeletal | 4 | 2024 | 1477 | 0.110 |
Why?
| | Pain | 1 | 2018 | 709 | 0.110 |
Why?
| | Pain, Intractable | 1 | 2012 | 8 | 0.110 |
Why?
| | Dopamine | 2 | 2005 | 235 | 0.100 |
Why?
| | Time Factors | 2 | 2021 | 6141 | 0.100 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2011 | 38 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 81 | 0.090 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 372 | 0.090 |
Why?
| | Antigen-Presenting Cells | 1 | 2011 | 153 | 0.090 |
Why?
| | Adolescent | 4 | 2021 | 17864 | 0.090 |
Why?
| | Pregnancy | 2 | 2018 | 5520 | 0.090 |
Why?
| | Movement | 2 | 2023 | 246 | 0.090 |
Why?
| | Leukocytes | 1 | 2011 | 277 | 0.090 |
Why?
| | Lymphocytes | 1 | 2011 | 334 | 0.080 |
Why?
| | Immunoglobulin G | 2 | 2023 | 776 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2013 | 3015 | 0.080 |
Why?
| | Spinal Cord | 2 | 2012 | 348 | 0.070 |
Why?
| | Aged | 4 | 2019 | 19119 | 0.070 |
Why?
| | MicroRNAs | 1 | 2013 | 603 | 0.070 |
Why?
| | Rats | 2 | 2005 | 4973 | 0.070 |
Why?
| | Pilot Projects | 2 | 2021 | 1375 | 0.070 |
Why?
| | Immunologic Memory | 2 | 2019 | 313 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 57 | 0.060 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2005 | 152 | 0.060 |
Why?
| | Risk Factors | 1 | 2018 | 8642 | 0.060 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2005 | 134 | 0.060 |
Why?
| | Animals | 4 | 2023 | 31867 | 0.060 |
Why?
| | Organ Specificity | 1 | 2005 | 270 | 0.060 |
Why?
| | Cytoplasm | 1 | 2005 | 256 | 0.060 |
Why?
| | Species Specificity | 1 | 2005 | 548 | 0.060 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2003 | 21 | 0.060 |
Why?
| | Models, Biological | 1 | 2011 | 1636 | 0.060 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2004 | 68 | 0.060 |
Why?
| | Osteolysis | 1 | 2003 | 12 | 0.060 |
Why?
| | Nerve Growth Factors | 1 | 2004 | 71 | 0.060 |
Why?
| | Cytokines | 1 | 2011 | 1843 | 0.050 |
Why?
| | Rats, Inbred F344 | 1 | 2003 | 241 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 744 | 0.050 |
Why?
| | Pluripotent Stem Cells | 1 | 2004 | 63 | 0.050 |
Why?
| | Crotonates | 1 | 2022 | 3 | 0.050 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 2022 | 3 | 0.050 |
Why?
| | Toluidines | 1 | 2022 | 6 | 0.050 |
Why?
| | Hydroxybutyrates | 1 | 2022 | 10 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 1 | 2011 | 1002 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2005 | 556 | 0.050 |
Why?
| | Arm | 1 | 2023 | 104 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2022 | 46 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2024 | 428 | 0.050 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 122 | 0.050 |
Why?
| | Cell Division | 1 | 2003 | 758 | 0.050 |
Why?
| | Nitriles | 1 | 2022 | 152 | 0.050 |
Why?
| | Heart | 1 | 2005 | 610 | 0.050 |
Why?
| | Base Sequence | 1 | 2005 | 2119 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 524 | 0.050 |
Why?
| | Gray Matter | 1 | 2022 | 68 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 250 | 0.050 |
Why?
| | MART-1 Antigen | 1 | 2021 | 10 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 133 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 448 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2024 | 746 | 0.050 |
Why?
| | Research Report | 1 | 2021 | 75 | 0.050 |
Why?
| | Electric Stimulation | 1 | 2021 | 261 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2796 | 0.050 |
Why?
| | Cell Survival | 1 | 2003 | 1022 | 0.040 |
Why?
| | Neuroimaging | 1 | 2022 | 251 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 285 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 522 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2020 | 60 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 299 | 0.040 |
Why?
| | Drug Substitution | 1 | 2019 | 46 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2023 | 481 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2019 | 133 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 22 | 0.040 |
Why?
| | Motor Skills | 1 | 2019 | 81 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1523 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 56 | 0.040 |
Why?
| | Hand | 1 | 2019 | 134 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2021 | 675 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 66 | 0.040 |
Why?
| | Mice | 2 | 2023 | 14927 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1127 | 0.040 |
Why?
| | Knee Joint | 1 | 2021 | 324 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 127 | 0.040 |
Why?
| | Leg | 1 | 2019 | 227 | 0.040 |
Why?
| | Homeostasis | 1 | 2021 | 578 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1169 | 0.040 |
Why?
| | Liver | 1 | 2005 | 1681 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4411 | 0.040 |
Why?
| | Headache | 1 | 2018 | 131 | 0.040 |
Why?
| | Organ Size | 1 | 2018 | 444 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1214 | 0.040 |
Why?
| | Internet | 1 | 2021 | 600 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2003 | 2715 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2004 | 1700 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 182 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 340 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 4904 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 157 | 0.030 |
Why?
| | Risk | 1 | 2017 | 815 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 3334 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2318 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2366 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 955 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 1879 | 0.030 |
Why?
| | Genetic Markers | 1 | 2013 | 323 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1321 | 0.030 |
Why?
| | Prospective Studies | 1 | 2024 | 6232 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2023 | 5040 | 0.030 |
Why?
| | Phosphorylation | 1 | 2016 | 1572 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 387 | 0.020 |
Why?
| | Down-Regulation | 1 | 2013 | 599 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 799 | 0.020 |
Why?
| | Pain Measurement | 1 | 2012 | 448 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1136 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 289 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1812 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6357 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2551 | 0.020 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2004 | 16 | 0.010 |
Why?
| | Cell Shape | 1 | 2004 | 54 | 0.010 |
Why?
| | Mesencephalon | 1 | 2004 | 57 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 105 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 96 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 201 | 0.010 |
Why?
| | Stem Cell Transplantation | 1 | 2004 | 149 | 0.010 |
Why?
| | Corpus Striatum | 1 | 2004 | 125 | 0.010 |
Why?
| | United States | 1 | 2018 | 12226 | 0.010 |
Why?
| | Astrocytes | 1 | 2004 | 162 | 0.010 |
Why?
| | Parkinson Disease | 1 | 2004 | 323 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 2191 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 3896 | 0.010 |
Why?
| | Phenotype | 1 | 2004 | 2815 | 0.010 |
Why?
|
|
Alvarez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|